

# 우울증의 약물치료

# Pharmacotherapy in the Treatment of Depression

가

505

---

In - Ho Paik, M.D. • Chi - Un Pae, M.D.

Department of Psychiatry

The Catholic University of Korea, College of Medicine

Kangnam St. Mary's Hospital

E - mail : [nppih@catholic.ac.kr](mailto:nppih@catholic.ac.kr) · [pae@catholic.ac.kr](mailto:pae@catholic.ac.kr)

3 5

, 2020

2 가

15% .

25%가

7 5 가

## Abstract

Some new antidepressants including mirtazapine and citalopram appear to have promising efficacy and tolerability in the treatment of depression. For most major depression, all antidepressant drugs have equal efficacy. The choice of antidepressant drug needs to be tailored to a particular patient's medical condition and personal preferences. It is likely that adverse effects are the major determinant in the choice of antidepressant for a particular patient. However, in treating conditions other than depression, the efficacy of the antidepressant drug can be the primary issue of drug choice. In conclusion, we would like to discuss the current status and future direction in the treatment of depression.

**Keywords : Pharmacotherapy; Depression**

• •

• •

2

, 15% ,  
 ,  
 , ,  
 .  
 1.  
 가 ( , ,  
 10% )  
 3/1 2 , ,  
 . 가  
 .  
 가 , ,  
 , , , 가 가  
 .  
 ,  
 가 . 2.  
 1)  
 ,  
 ,  
 가  
 가  
 가  
 .  
 .  
 ( ) , ( ) 2)  
 , ( )  
 가 ? , ,  
 .  
 가 ,  
 , ,  
 , 가  
 .

가 . 가

가 가 .

가 .

가 4)

2 1 가 가

가

2 가

가 8~12 가

2 가

가 , .

가가 . 3.

1)

3)

가 ( ), ,

가 ( , )

가 , , , ,

가 , -

2 ,

selective serotonin reuptake inhibitors(SSRIs) , mo-

noamine oxidase inhibitor(MAOI) ,

가

가 , TCA SSRI가  
 가 venlafaxine nefa-  
 2) zodone 가

가 가 .  
 ,  
 . 4) 가

#### 4.

1) 가 가  
 가 가  
 가 가  
 가 , 5)  
 가 , 가  
 가 . 6~8  
 ,  
 2) 3~4  
 , 3~4  
 ( 25%  
 )  
 (tricyclic antidepressant, TCA) 가 가  
 가 , 4~6  
 TCA가, MAOI  
 가

#### 5.

가  
 50%  
 4~9 가  
 3)

가가

citalopram sertraline  
fluoxetine, paroxetine, fluvoxamine  
(nonlinear pharmacokinetics)  
steady state

6.

3 (2~3 ) 가 fluoxetine  
5 . 2 1 1  
가 가  
, 가  
paroxetine

6

fluoxetine 가 MAOI  
SSRIs(2 ) (5 ).  
SSRIs clearance , ,  
serotonin(5 - HT) . Fluvoxamine SSRI  
system 가 . TCA가 가 가  
5 - HT norepinephrine(NE) reuptake ,  
, SSRIs NE dopamine(DA) . 가 paroxetine  
5 - HT reuptake creatine(Cr) clearance가 30~60 ml/  
min 가 2 , 30 ml/min  
citalopram 가 SSRIs 5 - HT reup- 4 가  
take NE 3,000 , DA 22,000  
. SSRIs alpha - adrenergic, histamine,  
DA, muscarinic receptor low affinity 가 .  
SSRIs  
2~8 . 가  
SSRIs albumin alpha 1 - acid glycopro- 가  
tein albumin digoxin .  
warfarin SSRIs TCA SSRIs TCA  
cytochrome P450 isoenzyme

## Drug - Drug Interaction

TCA, SSRIs, 5HT -		10 ~ 20 mg/day	10 mg/
NE reuptake inhibitor	cytochrome P450 enzyme	day	4 40 mg
system	microsomal system	가 3 ~ 4	80 mg 가
SSRIs	cytochrome P 450 2D6 isoenzyme	40 mg	가
가	inhibitor	paroxetine	
2) Sertraline			
SSRIs	P450 isoenzyme( 3A3/4)	50 mg/day	200 mg /day
		fluoxetine	
3) Paroxetine			
	SSRIs	10 ~ 20 mg/day	, 2 ~ 3
MAOI		10 mg	60 mg/day 가
가	, serotonin syn-	fluoxetine	paro-
drome		xetine onset of action	fluoxetine
MAOI	fluoxetine 5 , SSRIs 2		
	SSRIs		
2	MAOI		
4) Citalopram			
		20 ~ 40 mg/day가	
	fluoxetine	onset	
2.			
SSRIs	TCA	MAOI	monotherapy 가 SSRIs lithi-
			um, psychostimulant, thyroid hormone, buspirone
			가 . fluoxetine
	가	가	nortryptiline
		SSRIs	bupropion
		seizure 가	bupropion
75 ~ 225 mg/day			
SSRIs tapering Bupropion			
300 ~ 450 mg			
1.			
1) Fluoxetine			
SSRIs	anxiety	depres-	

## 3.

fluoxetine, paroxetine, sertraline  
가  
SSRIs 6~8  
가  
SSRIs augmentation new  
generation agent  
citalopram stroke depression  
citalopram fluoxetine 10 mg/day  
amitriptyline 25 mg/day  
가  
paroxetine  
nortriptyline 가 , nortriptyline  
가  
SSRIs  
가 가 nortriptyline  
mirtazapine

## 4.

SSRIs bupropion  
fluoxetine imipramine double blind study  
fluoxetine 86%, imipramine 57%, placebo  
38%  
fluoxetine  
TCA SSRIs가 가  
bupropion 가  
6~12

## 5.

SSRIs

SSRIs

1. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. *CNS Drug Rev* 2001 ; 7 : 249 - 64
2. Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine : a review. *J Clin Psychiatry* 1998 ; 59(Suppl 14) : 4 - 7
3. Feighner JP. Mechanism of action of antidepressant medications. *J Clin Psychiatry* 1999 ; 60 (Suppl 4) : 4 - 11
4. Frazer A. Pharmacology of antidepressants. *J Clin Psychopharmacol* 1997 ; 17 (Suppl 1) : S2 - 18
5. Keck PE Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. *J Clin Psychiatry* 1998 ; 59 (Suppl 6) : 74 - 81
6. Kent JM. SNaRIs, NaSSAs, and NaRIs : new agents for the treatment of depression. *Lancet* 2000 ; 355 : 911 - 8
7. Lenox RH, McNamara RK, Papke RL, Manji HK. Neurobiology of lithium : an update. *J Clin Psychiatry* 1998 ; 59 (Suppl 6) : 37 - 47

- 
8. Licht RW. Drug treatment of mania : a critical review. *Acta Psychiatr Scand* 1998 ; 97(6) : 387 - 97
  9. Macdonald KJ, Young LT. Newer antiepileptic drugs in bipolar disorder : rationale for use and role in therapy. *CNS Drugs* 2002 ; 16(8) : 549 - 62
  10. Masand PS, Gupta S. Selective serotonin - reuptake inhibitors : an update. *Harv Rev Psychiatry* 1999 ; 7 : 69 - 84
  11. Sadock BJ, Sadock VA. *Synopsis of Psychiatry*. 9th ed. Philadelphia : Williams & Wilkins, 2003
  12. Schatzberg AF. Clinical efficacy of reboxetine in major depression. *J Clin Psychiatry* 2000 ; 61 (Suppl 10) : 31 - 8
  13. Schatzberg AF, Cole JO, DMH CD. *Manual of clinical psychopharmacology*. 4th ed. Washington : American Psychiatric Publishing, Inc, 2003